EVOK News and Press, Evoke Pharma Inc. From 03/10/22

SOLANA BEACH, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that together with the research team at H.C. Wainwright & Co., it will host ...

Evoke Pharma, Inc. (EVOK) Q4 2021 Earnings Conference Call March 8, 2022, 4:30 PM ET Company Participants Dave Gonyer – Chief Executive Officer Matt D’Onfrio – Chief Business Officer Chris Quesenberry – Gimoti’s Chief Commercial Officer from EVERSANA Confere...

Evoke Pharma press release (NASDAQ:EVOK): Q4 GAAP EPS of $0.05 beats by $0.13. Revenue of $0.36M (+1700.0% Y/Y) misses by $0.15M. For further details see: Evoke Pharma GAAP EPS of $0.05 beats by $0.13, revenue of $0.36M misses by $0.15M

Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare professionals SOLANA BEACH, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pha...

SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2021 financ...

SOLANA BEACH, Calif., and CHICAGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti (metoclopramide) nasal spray (GIMOTI), today ann...

New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com Expanded Coverage with recent New York Medicaid Approval SOLANA BEACH, Calif., Feb. 17, 2022 (GLOBE NEW...

Evoke Pharma (EVOK +2.2%) and Eversana Life Science Services extended their agreement to continue collaborating on the commercialization and distribution of Gimoti (metoclopramide) nasal spray in the U.S. through the end of 2026. According to the original 2020 agreement, Evoke retai...

SOLANA BEACH, Calif. and CHICAGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Services, LLC, an independent provider of global commercial...

SOLANA BEACH, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases, today announced that the Company will participate in the H.C. Wainwright BIOCONNECT Conference ...